Literature DB >> 25218235

Digital gene expression analysis of the pathogenesis and therapeutic mechanisms of ligustrazine and puerarin in rat atherosclerosis.

Rao Fu1, Yuting Zhang1, Yiran Guo2, Yanling Zhang3, Ying Xu1, Fang Chen4.   

Abstract

Atherosclerosis (AS) is the leading cause of death in modern societies. Active substance from Traditional Chinese Medicine has been used for the treatment of AS, such as ligustrazine and puerarin. However, the pathogenesis of AS and the curative mechanisms of ligustrazine and puerarin stay unclear. In this work, we attempted to figure out these questions using a rat AS model and digital gene expression (DGE) system. Our results showed that DGE sequencing outcomes were high quality and reproductively. Differentially expressed genes were obtained from different comparisons. The Gene Ontology (GO) analysis revealed that mainly enriched GO terms due to the drug treatment were the same as those obtained from the control group vs. the AS model group. Pathway analysis indicated that metabolic pathways, oxidative phosphorylation, and PPAR single pathways were enriched in all comparisons. Our work provided a comprehensive basis for a better understanding of the pathogenesis of AS and the curative mechanisms of ligustrazine and puerarin.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Digital gene expression; Ligustrazine; Pathogenesis; Puerarin

Mesh:

Substances:

Year:  2014        PMID: 25218235     DOI: 10.1016/j.gene.2014.09.015

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Effect of Tetramethylpyrazine on Atherosclerosis and SCAP/SREBP-1c Signaling Pathway in ApoE-/- Mice Fed with a High-Fat Diet.

Authors:  Ying Zhang; Pan Ren; Qunfu Kang; Weihong Liu; Sinai Li; Ping Li; Hongxu Liu; Juju Shang; Lei Zhang; Yanbing Gong; Mingxue Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-12       Impact factor: 2.629

2.  Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses.

Authors:  Guoyou Zhang; Yu Wang; Guoke Tang; Yuanzheng Ma
Journal:  BMC Complement Altern Med       Date:  2019-10-15       Impact factor: 3.659

Review 3.  Ligustrazine for the Treatment of Unstable Angina: A Meta-Analysis of 16 Randomized Controlled Trials.

Authors:  Suman Cao; Wenli Zhao; Huaien Bu; Ye Zhao; Chunquan Yu
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-26       Impact factor: 2.629

4.  Puerarin Inhibits oxLDL-Induced Macrophage Activation and Foam Cell Formation in Human THP1 Macrophage.

Authors:  Heng Zhang; Zhenhua Zhai; Hongyu Zhou; Yao Li; Xiaojie Li; Yuhan Lin; Weihong Li; Yueping Shi; Ming-Sheng Zhou
Journal:  Biomed Res Int       Date:  2015-10-21       Impact factor: 3.411

5.  Puerarin inhibits vascular smooth muscle cells proliferation induced by fine particulate matter via suppressing of the p38 MAPK signaling pathway.

Authors:  Qiang Wan; Zhongyong Liu; Yuping Yang
Journal:  BMC Complement Altern Med       Date:  2018-05-04       Impact factor: 3.659

Review 6.  Effects of Puerarin on the Prevention and Treatment of Cardiovascular Diseases.

Authors:  Yan-Xi Zhou; Hong Zhang; Cheng Peng
Journal:  Front Pharmacol       Date:  2021-12-07       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.